Библиография

Лимфома Ходжкина

• 1. Давыдов МИ., Аксель ЕМ. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Вестник РОНЦ им. ННБлохина РАМН. 2009; 20 (3); Прил. 1.
• 2. Клиническая онкогематология. Изд. 2-е. Руководство для врачей. Под ред. проф. МАВолковой. М.: Медицина, 2007; с. 679-723.
• 3. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.
• 4. Демина ЕА, Тумян Г.С., Унукова ЕН. и др. Современные возможности лечения первичных больных лимфомой Ходжкина и причины неудач лечения. Онкогематология. 2007; 2:24-30.
• 5. Engert A, FranklinJ Eich HTet al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial. JCO 2007; 3495-502.
• 6. Engert A PlutschowA, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-52.
• 7. Ткачев СИ., Демина ЕА, Трофимова ОП., Сахаровская В.Г. Современное лечение больных с ранними стадиями лимфомы Ходжкина.Вопросы онкологии. 2007;53 (1): 114-7.
• 8. Morschhauser F, Brice P, Ferme C et al. Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantationfor First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group. JCO 2008:5980-7.
• 9. Sieniawski M, Franklin J, Nogova L et al. Outcome of Patients Experiencing Progression or Relapse After Primary Treatment With Two Cycles of Chemotherapy and Radiotherapy for Early-StageFavorable Hodgkin's Lymphoma. JCO 2007; 25:2000-5.
• 10. Josting A Nogova L, Franklin J et al. Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. JCO 2005; 23: 1522-9.
• 11. Sureda A, Robinson S, Canals S et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JCO 2008; 26:455-62.
• 12. Gallamini A, Hutchings M, Rigacci L et al. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. JCO 2007; 25:3 746-52.
• 13. Cheson BD, Pfstner B, Juweid VE et al. Revised Response Criteria for Malignant Lymphoma:. JCO 2007; 25:579-86.
• 14. Federico M, Luminari S, Iannitto E et al. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. JCO 2009; 27: 805-11.
• 15. Behringer K Thielen I, Mueller H et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 2012; 23 (7): 1818-25.
• 16. Пылова ИВ., Шмаков РГ., Демина ЕА и др. Эффективность защиты яичников при проведении химиотерапии у женщин с лимфомой Ходжкина. Акушерство и гинекология. 2011; 7 (1): 40-5.
• 17. Engert A, Haverkamp H, Kobe C et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase3 non-inferiority trial. Lancet2012; 379 (9828): 1791-9.
• 18. Engert A, Bredenfed H, Dohner H et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica 2006; 91 (4): 546-9.
• 19. Sieber M, Bredenfed H, Josting A et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group. JCO 2003; 21 (9): 1734-9.
• 20. Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N EnglJ Med 2007;357 (19): 1916-27.
• 21. Borchmann P, Engert A, Pluetschow A et al. Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood (ASH Annual Meeting Abstracts) 2008; 112:367.
• 22. Ekstrand B, Lucas L, Horwitz S et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood2003; 101:4285-9.
• 23. Schulz H, Rehwald U, Morschhauser F et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood2008; 111: 109-11.
• 24. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse forpatients with residual disease afterfirst-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-94.
• 25. Hutchings M, Loft A Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood2006; 107:52-9.
• 26. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359 (9323): 2065-71.
• 27. Peggs KS, Hunter A, Chopra R et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet2005; 365 (9475): 1934-41.
• 28. Santoro A, Magagnoli M, Spina M et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007; 92:35-41.
• 29. Behringer K Thielen I, Mueller H et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD 14 trial. Ann Oncol 2012; 23 (7): 1818-25.
• 30. Eichenauer DA, Engert A Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma?Leuk Lymph 2009; 50 (11): 1733-4.
• 31. Meyer RM, Gospodarowicz MK, ConnorsJIM et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. N EnglJ Med 2012; 366:399-408.
• 32. Nogova L, Reineke T, Brillant C et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26:434-933. Jackson C, Sirohi B, Cunningham D et al. Lymphocyte-predominant Hodgkin lymphoma - clinical features and treatment outcomes from a 30-year experience. Annals of Oncology 2010; 21: 2061-8.
• 34. Advani RH, Horning SJ, Hoppe RT et al. Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. ASH Annual Meeting Abstracts 2011; 118:2686.
• 35. Swerdlow AJ, Higgins CD, Smith P et al. Second cancer risk after chemotherapyfor Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011; 29:4096-104.
• 36. El-Galaly T, Mylam KJ, Brown P et al. PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. Haematologica 2012; 97:931-6.
• 3 7. Puig N, Pintilie M, Seshadri T et al. Different response to salvage chemotherapy but similarpost-transplant outcomes in patients with relapsed and refractory Hodgkin’s lymphoma. Haematologica 2010; 95: 1496-502.
• 38. Connors JM. Positron Emission Tomography in the Management of Hodgkin Lymphoma Hematology 2011: p. 317-22.